Company
Lemaitre Vascular
Last checked: Nov 20, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
8
510(k), De Novo and PMA
Device trials
8
As lead sponsor, any status
Adverse event reports
413
Received Nov 1, 2025 to Nov 20, 2026
Recall records
85
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
Public company. Figures from its SEC financial statements.
Listed
LMAT
Nasdaq · LEMAITRE VASCULAR INC
Public float
$1.70B
Value of shares held by non-insiders on Jun 30, 2025
Revenue
$250M
Fiscal year ending Dec 31, 2025
Net income
$57.7M
Fiscal year ending Dec 31, 2025
R&D spending
$14.1M
Fiscal year ending Dec 31, 2025
Cash
$27.5M
As of Sep 30, 2026
Long-term debt
$169M
As of Sep 30, 2026
Shares outstanding
22.9M
As of Nov 2, 2026
Capital raised as a public company
Cash received from selling stock and borrowing, from each year's cash-flow statement in the annual report. Fiscal years, by the year each one ended.
| Year | IPO | Stock sold | Long-term debt | Convertible debt |
|---|---|---|---|---|
| 2024 | – | $6.4M | – | – |
| 2023 | – | $6.2M | – | – |
| 2022 | – | $3.5M | – | – |
| 2021 | – | $63.2M | – | – |
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
The investor database is free with an account
Sign up free with your name, company and ZIP code to see the 5%+ shareholders and government grant funders behind device companies.
Latest FDA decisions
- PhasTIPP510(k)
K212894 · Decided Mar 31, 2022 · 202 days after receipt
Device type: Stripper, Vein, External (DWQ) · Cardiology
7 more FDA decisions with a free account
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
- Evaluate Safety and Effectiveness of XenoSure Biological Patch in the Application of Cardiac RepairPivotal-lookingCompleted
NCT03176225 · 142 participants · Start Aug 15, 2017 · Primary completion Nov 15, 2020
Device: Close the defects with XenoSure Patch; Close the defects with Chest Polyester Patch · For: Heart Diseases
Sites: Beijing, China
7 more trials with a free account
Reports received
413
Received Nov 1, 2025 to Nov 20, 2026
Malfunction reports
365
88% of reports
Injury reports
47
11% of reports
Death reports
1
0.2% of reports
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 12 | 0 | 0 | 0 |
| Jan 24 | 26 | 2 | 0 | 0 |
| Feb 24 | 21 | 14 | 0 | 0 |
| Mar 24 | 15 | 7 | 0 | 0 |
| Apr 24 | 15 | 7 | 0 | 0 |
| May 24 | 14 | 1 | 0 | 0 |
| Jun 24 | 6 | 3 | 0 | 0 |
| Jul 24 | 17 | 15 | 0 | 0 |
| Aug 24 | 12 | 3 | 1 | 0 |
| Sep 24 | 37 | 1 | 1 | 0 |
| Oct 24 | 14 | 1 | 1 | 0 |
| Nov 24 | 29 | 0 | 0 | 0 |
| Dec 24 | 16 | 3 | 0 | 0 |
| Jan 25 | 19 | 0 | 0 | 0 |
| Feb 25 | 22 | 2 | 0 | 0 |
| Mar 25 | 17 | 3 | 0 | 0 |
| Apr 25 | 23 | 1 | 0 | 0 |
| May 25 | 8 | 2 | 0 | 0 |
| Jun 25 | 10 | 1 | 0 | 0 |
| Jul 25 | 29 | 0 | 0 | 0 |
| Aug 25 | 16 | 4 | 0 | 0 |
| Sep 25 | 24 | 6 | 0 | 0 |
| Oct 25 | 21 | 1 | 1 | 0 |
| Nov 25 | 19 | 6 | 0 | 0 |
| Dec 25 | 16 | 6 | 0 | 0 |
| Jan 26 | 12 | 2 | 0 | 0 |
| Feb 26 | 23 | 3 | 0 | 0 |
| Mar 26 | 25 | 1 | 0 | 0 |
| Apr 26 | 44 | 3 | 1 | 0 |
| May 26 | 19 | 4 | 0 | 0 |
| Jun 26 | 50 | 2 | 0 | 0 |
| Jul 26 | 58 | 4 | 0 | 0 |
| Aug 26 | 29 | 9 | 0 | 0 |
| Sep 26 | 44 | 4 | 0 | 0 |
| Oct 26 | 26 | 3 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
7 more in this ranking with a free account
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
7 more in this ranking with a free account
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0117-2027 · Started Aug 28, 2026 · Posted by FDA Oct 7, 2026
Reason given: Devices failed in process testing related to the amount of pull force it can sustain prior to the balloon components failing.
Cause as FDA categorized it: Under Investigation by firm · Device type: Catheter, Embolectomy (DXE)
84 more recall records with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.